Is Scinai Immunotherapeutics Ltd. (SCNI) Stock Halal or Haram?
Scinai Immunotherapeutics Ltd. (SCNI) - Not Halal (Non-Compliant)
Scinai Immunotherapeutics Ltd. (SCNI) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
Sector
Healthcare
Industry
Biotechnology
Result
Pass
Reason
The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.
Financial Ratios
Debt Ratio
Value: 37.2% | Threshold: 30% | Result: Fail
Cash & Interest-bearing Securities Ratio
Value: 27.5% | Threshold: 30% | Result: Pass
Non-Permissible Income Ratio
Value: 1.5% | Threshold: 5% | Result: Pass
Dividend Purification
Purification percentage: 1.53%.Based on the company's financial statements, approximately 1.53% of dividend income should be donated to charity for purification. This is derived from identified interest income (1.53% of total income). Some scholars may differ on the exact calculation method.
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Based on the company's financial statements, approximately 1.53% of dividend income should be donated to charity for purification. This is derived from identified interest income (1.53% of total income). Some scholars may differ on the exact calculation method.
Uses quarterly data
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
IsraelNASDAQHealthcare
Screened using AAOIFI Standard No. 21 on October 13, 2026. Financial ratios compared against market capitalization. Different methodologies may produce different results. Learn how we screen.
Screened using AAOIFI Shariah Standard No. 21 (3 ratios). Debt and interest-bearing deposits must each be under 30% of market capitalization, and non-permissible income under 5% of total income. This screening is for educational purposes only and does not constitute a fatwa or religious ruling. Results are based on publicly available financial data and automated analysis. Users should consult qualified Islamic scholars and financial advisors for personal investment decisions. Financial data may be delayed or incomplete. Past compliance does not guarantee future status.
Verdict history
Free with an account.
No verdict changes recorded since first screened on Sep 14, 2026. We started recording changes on Oct 19, 2026.
Dates are when Mizaan recorded the change. Tracked and watched stocks are re-checked weekly; other stocks are re-screened on demand.
Get More on the Mizaan App
Live charts, market cap, financials, AI business analysis, portfolio tracking, and compliance alerts — all on your phone.
Frequently Asked Questions
According to AAOIFI Shariah screening standards, Scinai Immunotherapeutics Ltd. (SCNI) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Scinai Immunotherapeutics Ltd.'s interest income ratio is 27.5% of total revenue. AAOIFI standards require this to be below 30%.
SCNI is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
Scinai Immunotherapeutics Ltd.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
You can save SCNI to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Dividends from Scinai Immunotherapeutics Ltd. require purification. Approximately 1.53% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
Is Scinai Immunotherapeutics Ltd. (SCNI) stock halal to invest in?
According to AAOIFI Shariah screening standards, Scinai Immunotherapeutics Ltd. (SCNI) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Does Scinai Immunotherapeutics Ltd. have any interest income?
Scinai Immunotherapeutics Ltd.'s interest income ratio is 27.5% of total revenue. AAOIFI standards require this to be below 30%.
What guidelines are used to determine if SCNI stock is Shariah-compliant?
SCNI is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
How often is Scinai Immunotherapeutics Ltd. stock reviewed for Shariah compliance?
Scinai Immunotherapeutics Ltd.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
How can I stay updated on Scinai Immunotherapeutics Ltd.'s compliance status?
You can save SCNI to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Are dividends from Scinai Immunotherapeutics Ltd. stock considered halal?
Dividends from Scinai Immunotherapeutics Ltd. require purification. Approximately 1.53% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Do I need to pay Zakat on my Scinai Immunotherapeutics Ltd. shares?
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
